Statins are some of the most widely prescribed drugs in the world. Their use has expanded into many areas such as autoimmune disorders, cancer, obesity, and Alzheimer’s disease. However, it is cholesterol that drives the statin market. The US market for statins nearly tripled when the National Cholesterol Education Program (NCEP) revised its guidelines to recommend statins as primary prevention. Although the NCEP panel cited randomized trials to support statin therapy for primary prevention of occlusive cardiovascular disease, a report in Lancet questioned the conclusion.